A new inhaled therapy targeting lung inflammation shows promise in reducing damage and improving recovery after severe ...
A quiet signal inside a tumor may soon guide how surgeons treat early lung cancer. Researchers now report that hidden genetic ...
Olverembatinib, an investigational multikinase inhibitor (approved in China for CML), inhibits Src-family kinases (e.g., Lyn, ...
Soley Therapeutics, a biotechnology company advancing novel therapeutics informed by integrated cell stress biology, today ...
Accent Therapeutics, a clinical-stage biopharmaceutical company pioneering novel small molecule precision cancer therapies, ...
Exceptional measures of efficacy observed in THIO-101 Phase 2 trial to date include disease control, response rates, and survival data well above ...
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced that the first ...
The data to be presented show that Geminii's bioelectronic therapy slowed tumor growth, extended survival, and enhanced the activity of chemoradiation in multiple preclinical NSCLC models without ...
Organoids are miniature, simplified versions of an organ. Over the past two decades, scientists have developed them for the ...
Exceptional measures of efficacy observed in THIO-101 Phase 2 trial to date include disease control, response rates, and survival data well above standard of care benchmarks 50,000 advanced NSCLC diag ...
Ideaya Biosciences begins patient dosing in phase 1 trial of IDE574, a potential first-in class dual inhibitor of KAT6/7 to target multiple solid tumour indications, including bre ...
New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results